Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

175.90 

2.10 1.2%

as of May 12 '21

52 Week Range:

101.81 180.39


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Equity (BVPS) 0.76
3.33
19.32
21.50
22.11
25.50
28.69
41.23
52.65
54.41
60.12
growth rate 338.2% 480.2% 11.3% 2.8% 15.3% 12.5% 43.7% 27.7% 3.3% 10.5%
Earnings BIT 32.78
124.98
177.36
372.00
450.02
557.92
640.10
613.84
715.93
642.35
765.46
growth rate 281.3% 41.9% 109.7% 21.0% 24.0% 14.7% -4.1% 16.6% -10.3% 19.2%
Avg.PE 23.64
14.47
12.27
36.10
182.89
24.89
23.44
24.37
14.88
13.28
50.79
growth rate -38.8% -15.2% 194.2% 406.6% -86.4% -5.8% 4.0% -38.9% -10.8% 282.5%
ROA 26.96
64.21
26.00
10.29
2.09
9.84
9.73
9.83
8.66
9.74
3.95
growth rate 138.2% -59.5% -60.4% -79.7% 370.8% -1.1% 1.0% -11.9% 12.5% -59.5%
ROE 107.30
111.92
43.92
17.90
4.38
22.19
22.83
21.26
16.35
17.84
7.05
growth rate 4.3% -60.8% -59.2% -75.5% 406.6% 2.9% -6.9% -23.1% 9.1% -60.5%
ROIC 112.85
26.89
13.74
4.06
13.51
13.21
13.03
11.85
12.48
6.04
growth rate -76.2% -48.9% -70.5% 232.8% -2.2% -1.4% -9.1% 5.3% -51.6%
Cur. Ratio 1.24
3.77
2.88
4.24
4.69
5.55
2.91
3.29
3.57
4.47
4.34
growth rate 204.0% -23.6% 47.2% 10.6% 18.3% -47.6% 13.1% 8.5% 25.2% -2.9%
Quick Ratio 1.12
3.64
2.42
3.73
4.01
5.29
2.56
2.81
3.15
3.93
3.87
growth rate 225.0% -33.5% 54.1% 7.5% 31.9% -51.6% 9.8% 12.1% 24.8% -1.5%
Leverage 4.44
1.32
1.75
1.73
2.44
2.10
2.56
1.89
1.89
1.78
1.79
growth rate -70.3% 32.6% -1.1% 41.0% -13.9% 21.9% -26.2% 0.0% -5.8% 0.6%
Balance Sheet Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Acct.Receivable 22.10
34.37
75.00
125.00
186.37
209.69
234.24
224.13
263.84
355.99
396.49
growth rate 55.5% 118.2% 66.7% 49.1% 12.5% 11.7% -4.3% 17.7% 34.9% 11.4%
Acct.Payable 39.91
16.00
21.00
25.13
21.81
22.42
24.37
40.60
45.73
26.95
growth rate -59.9% 31.3% 19.7% -13.2% 2.8% 8.7% 66.6% 12.6% -41.1%
Cur.Assets 74.50
199.13
552.00
865.00
1,015.85
1,257.67
748.07
968.28
1,234.01
1,630.27
2,839.57
growth rate 167.3% 177.2% 56.7% 17.4% 23.8% -40.5% 29.4% 27.4% 32.1% 74.2%
Total Assets 135.70
253.57
1,966.00
2,238.00
3,338.96
3,332.61
4,800.23
5,123.67
5,203.49
5,538.90
6,535.90
growth rate 86.9% 675.3% 13.8% 49.2% -0.2% 44.0% 6.7% 1.6% 6.5% 18.0%
Cash 44.80
82.08
387.00
637.00
684.04
988.79
365.96
386.04
309.62
637.34
1,057.77
growth rate 83.2% 371.5% 64.6% 7.4% 44.6% -63.0% 5.5% -19.8% 105.9% 66.0%
Inventory 5.00
3.91
27.00
29.00
30.04
19.45
34.05
43.25
52.96
78.61
95.40
growth rate -21.8% 590.7% 7.4% 3.6% -35.2% 75.1% 27.0% 22.5% 48.4% 21.4%
Cur.Liabilities 59.90
52.87
192.00
204.00
216.80
226.64
257.41
293.95
345.49
364.49
653.75
growth rate -11.7% 263.2% 6.3% 6.3% 4.5% 13.6% 14.2% 17.5% 5.5% 79.4%
Liabilities 105.20
60.79
845.00
943.00
1,967.75
1,733.97
2,922.89
2,410.58
2,446.07
2,427.92
2,876.16
growth rate -42.2% 1,290.2% 11.6% 108.7% -11.9% 68.6% -17.5% 1.5% -0.7% 18.5%
LT Debt 24.60
0.00
427.00
544.00
1,333.00
1,150.86
1,993.53
1,540.43
1,563.03
1,574.53
1,848.52
growth rate -100.0% 27.4% 145.0% -13.7% 73.2% -22.7% 1.5% 0.7% 17.4%
Equity 30.60
192.79
1,121.29
1,295.53
1,371.14
1,598.65
1,877.34
2,713.10
2,757.42
3,110.98
3,659.75
growth rate 530.0% 481.6% 15.5% 5.8% 16.6% 17.4% 44.5% 1.6% 12.8% 17.6%
Common Shares 39.00
47.00
60.00
62.00
63.00
63.00
62.00
61.00
61.00
58.00
57.00
growth rate 20.5% 27.7% 3.3% 1.6% 0.0% -1.6% -1.6% 0.0% -4.9% -1.7%
Cash Flow Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Capital Expenditures 0.70
1.28
6.00
10.00
36.35
35.96
9.69
28.95
20.37
40.14
15.00
growth rate 82.7% 369.1% 66.7% 263.5% -1.1% -73.1% 198.9% -29.6% 97.0% -62.6%
Cash Dividends 0.00 0.00 0.00
growth rate
Cash From OA 58.90
151.60
250.00
288.00
407.61
531.94
592.39
693.09
798.90
776.40
899.65
growth rate 157.4% 64.9% 15.2% 41.5% 30.5% 11.4% 17.0% 15.3% -2.8% 15.9%
FCF per Share 1.37
2.75
3.78
4.78
2.08
7.62
5.56
9.32
10.35
12.45
8.04
growth rate 100.7% 37.5% 26.5% -56.5% 266.4% -27.0% 67.6% 11.1% 20.3% -35.4%
Sale Purchase of Stock 16.42
25.00
-105.78
58.49
40.52
24.17
31.82
growth rate 52.3% -100.0% 100.0% -30.7% -40.3% 31.7%
FCF 54.00
146.00
227.00
272.00
167.00
496.00
409.00
579.00
667.00
594.00
520.00
growth rate 170.4% 55.5% 19.8% -38.6% 197.0% -17.5% 41.6% 15.2% -10.9% -12.5%
Income Statement Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Sales 173.80
272.28
586.00
872.00
1,172.88
1,324.80
1,487.97
1,618.69
1,890.92
2,161.76
2,363.57
growth rate 56.7% 115.2% 48.8% 34.5% 13.0% 12.3% 8.8% 16.8% 14.3% 9.3%
Op.Income 57.80
124.98
261.00
372.00
450.02
557.92
640.10
613.84
715.93
642.35
765.46
growth rate 116.2% 108.8% 42.5% 21.0% 24.0% 14.7% -4.1% 16.6% -10.3% 19.2%
IBT 0.00
124.98
177.36
307.95
151.56
435.93
532.07
440.11
527.26
450.21
272.13
growth rate 41.9% 73.6% -50.8% 187.6% 22.1% -17.3% 19.8% -14.6% -39.6%
Net Income 32.80
124.98
261.00
216.00
58.39
329.54
396.83
487.85
447.10
523.37
238.62
growth rate 281.1% 108.8% -17.2% -73.0% 464.4% 20.4% 22.9% -8.4% 17.1% -54.4%
EPS 0.83
2.67
4.79
3.51
0.93
5.23
6.41
7.96
7.30
9.09
4.22
growth rate 221.7% 79.4% -26.7% -73.5% 462.4% 22.6% 24.2% -8.3% 24.5% -53.6%
Gross Profit 160.20
258.34
524.00
774.00
1,065.96
1,222.28
1,382.59
1,508.51
1,769.38
2,033.83
2,214.65
growth rate 61.3% 102.8% 47.7% 37.7% 14.7% 13.1% 9.1% 17.3% 15.0% 8.9%
R&D 25.60
14.12
20.48
41.63
85.18
133.45
160.40
198.44
226.62
299.73
335.38
growth rate -44.8% 45.0% 103.3% 104.6% 56.7% 20.2% 23.7% 14.2% 32.3% 11.9%

Quarterly Statements

Item Name Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Earnings BIT 148.72
201.13
206.21
209.41
growth rate 35.2% 2.5% 1.6%
Balance Sheet Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Acct.Receivable 317.30
351.92
361.66
396.49
413.98
growth rate 10.9% 2.8% 9.6% 4.4%
Acct.Payable 66.31
50.04
67.06
26.95
77.74
growth rate -24.5% 34.0% -59.8% 188.5%
Cur.Assets 1,517.64
2,302.35
2,555.57
2,839.57
3,166.90
growth rate 51.7% 11.0% 11.1% 11.5%
Total Assets 5,215.30
6,066.50
6,291.96
6,535.90
6,756.47
growth rate 16.3% 3.7% 3.9% 3.4%
Cash 701.60
786.08
741.94
1,057.77
2,097.53
growth rate 12.0% -5.6% 42.6% 98.3%
Inventory 85.61
92.53
91.40
95.40
115.48
growth rate 8.1% -1.2% 4.4% 21.1%
Cur.Liabilities 396.12
409.96
642.13
653.75
752.09
growth rate 3.5% 56.6% 1.8% 15.0%
Liabilities 2,406.80
2,924.70
2,914.76
2,876.16
growth rate 21.5% -0.3% -1.3%
LT Debt 1,578.43
2,069.85
1,843.69
1,848.52
growth rate 31.1% -10.9% 0.3%
Equity 2,808.50
3,141.81
3,377.20
3,659.75
3,797.69
growth rate 11.9% 7.5% 8.4% 3.8%
Common Shares 0.01
0.01
0.01
0.01
0.01
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Capital Expenditures 4.83
2.69
3.37
4.12
growth rate -44.3% 25.2% 22.1%
Cash Dividends
growth rate
Cash From OA 272.97
182.52
257.89
186.27
285.00
growth rate -33.1% 41.3% -27.8% 53.0%
Sale Purchase of Stock
growth rate
FCF 268.14
179.83
254.52
182.16
growth rate -32.9% 41.5% -28.4%
Income Statement Mar '20 Jun '20 Sep '20 Dec '20 Mar '21
Sales 534.73
562.44
600.89
665.52
607.58
growth rate 5.2% 6.8% 10.8% -8.7%
Op.Income 148.72
201.13
206.21
209.41
growth rate 35.2% 2.5% 1.6%
IBT -209.12
169.56
167.52
144.18
growth rate 100.0% -1.2% -13.9%
Net Income -157.83
114.80
148.23
133.41
121.83
growth rate 100.0% 29.1% -10.0% -8.7%
EPS
growth rate
Gross Profit 506.07
534.43
558.79
615.36
growth rate 5.6% 4.6% 10.1%
R&D 86.11
78.92
78.65
91.70
76.57
growth rate -8.3% -0.4% 16.6% -16.5%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

C (59.69)

YOY Growth Grade:

C (64.54)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 40.96 41.68 9.72
EPS / Growth 12.9% 4.22 11.4%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 22.9%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 11.4% 15.8% 15.8%
Future PE 9.72 27.40 27.40
Future EPS 12.42 18.23 18.23
Value Price
MOS %
29.83
-83.0%
123.49
-29.8%
123.49
-29.8%
MOS Price 14.92 61.75 61.75
IRT 15.37 12.97 12.97

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.